arrow
P

Paula F. Ypma

Haga Hospital
H指数:24
被引数:2,246

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multiple myeloma in the Netherlands: 35-year trends in incidence and survival

荷兰多发性骨髓瘤:35年发病率和生存趋势

Leukemia
IF13.4
2026-10-220
OAAI
Psychometric properties and outcomes of the PROMIS® Sexual Function and Satisfaction measures in individuals with congenital bleeding disorders

PROMIS®性功能与满意度量表的测量属性和结果:先天性出血障碍患者研究

2026-09-020
OAAI
Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome

揭示超脆弱人群:非移植适应症的 newly diagnosed 多发性骨髓瘤患者中的一个独特亚组,具有较差的临床结局

2025-12-080
OAAI
Pharmacokinetic-guided dose reduction of emicizumab in congenital hemophilia A: Interim Analysis of the DosEmi Study

先天性血友病A中基于药代动力学的依米珠单抗剂量调整:DosEmi研究的期中分析

2025-11-070
OAAI
Adaptive designs in randomized clinical trials: reanalysis of the HOVON87/NMSG18 multiple myeloma trial

随机临床试验中的适应性设计:HOVON87/NMSG18多发性骨髓瘤试验的再分析

2025-10-300
OAAI
Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab

使用G-CSF联合或不联合环磷酰胺在自体干细胞移植前动员造血干细胞,用于接受含或不含达雷木单抗诱导治疗的新诊断多发性骨髓瘤患者

2025-08-300
PRE
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study

利扎布鲁替尼(Rilzabrutinib)的疗效和安全性结果:一项在免疫性血小板减少症患者中的口服布鲁顿酪氨酸激酶抑制剂Ⅱ期B部分研究

2025-01-221
OA
Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial
2024-11-200
OAAI
Frailty Subgroups Determine Heterogeneous Outcomes in Elderly Patients with Newly-Diagnosed Multiple Myeloma- Long-Term Follow-up of the HOVON 143 Trial

脆弱性亚组确定新诊断多发性骨髓瘤老年患者异质性结局—HOVON 143试验的长期随访

BLOOD
IF23.1
2024-11-051
PRE
Pharmacokinetic-Guided Reduction of Emicizumab in Patients with Congenital Hemophilia a in the Netherlands: Interim Analysis from the Dosemi Study

荷兰先天性血友病A患者中基于药代动力学的依米珠单抗减量:Dosemi研究的期中分析

BLOOD
IF23.1
2024-11-050
PRE
Bispecific Antibodies for Multiple Myeloma in the Real World: Lessons Learnt from a Nation-Wide Dutch Observational Registry

双特异性抗体在多发性骨髓瘤真实世界中的应用:来自荷兰全国性观察性登记研究的经验教训

BLOOD
IF23.1
2024-11-050
PRE
Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial
2024-08-010
OAAI
Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
2024-07-041
OAAI
Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B

药代动力学指导的血友病A和B因子浓缩物预防性给药的预测性能

2024-03-010
OAAI
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
2023-09-016
OAAI
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
2023-09-011
OAAI
Predictors of the corrected count increment after platelet transfusion, a secondary analysis of the PACER randomized controlled trial
2023-08-210
OA
Transition readiness among adolescents and young adults with haemophilia in the Netherlands: Nationwide questionnaire study
2023-08-210
OA